Miltenyi Biomedicine is a biopharmaceutical company that develops innovative cell and gene therapies. We are committed to bring cancer treatments and regenerative therapies to patients with unmet medical needs worldwide. We work in partnership with physicians and other healthcare providers to expand access to new therapies. 
Our clinical research program includes: CAR T, CAR NK, our proprietary Adapter CAR™ and induced pluripotent stem cells (iPSC) technologies. 
For more information, please visit our website at www.miltenyibiomedicine.com.

Biotechnology

Clinical Trials

Medical Devices

Pharmaceutical

Miltenyi Biomedicine

Toon Overstijns

Michael Terhoeven

Dr. Sandra Karitzky

Peter Toth

Hans-Juergen Fuelle

Tomasz Skrzypczak

Hans - Jürgen Fülle

Andreas Woitossek

Anna Wijatyk

The Leadership Team at Miltenyi Biomedicine is responsible for setting the strategic direction and vision of the company. They oversee regulatory affairs, business development, commercial strategy, and medical operations to ensure the successful development and delivery of innovative cell and gene therapies. Their collaborative efforts ensure that the company meets its mission to bring pioneering cancer treatments and regenerative therapies to patients globally.

Leadership Team

Clinical Research and Development

Regulatory Affairs and Market Access

Leadership Team

About

Team members

Other teams at Miltenyi Biomedicine

Clinical Research and Development

Regulatory Affairs and Market Access